Novozymes A/S (OTCMKTS:NVZMY) Raised to “Strong-Buy” at Barclays

Novozymes A/S (OTCMKTS:NVZMY) was upgraded by equities research analysts at Barclays to a “strong-buy” rating in a note issued to investors on Monday,Zacks.com reports.

Several other brokerages have also recently commented on NVZMY. Berenberg Bank raised Novozymes A/S to a “strong-buy” rating in a report on Tuesday, September 24th. Citigroup cut Novozymes A/S from a “neutral” rating to a “sell” rating in a research note on Thursday, October 17th.

Novozymes A/S Stock Performance

OTCMKTS:NVZMY opened at $56.53 on Monday. The stock has a market cap of $26.47 billion, a price-to-earnings ratio of 35.78, a PEG ratio of 3.87 and a beta of 0.90. The business has a fifty day moving average of $65.88 and a 200-day moving average of $63.85. Novozymes A/S has a 1 year low of $49.99 and a 1 year high of $72.50.

Novozymes A/S Company Profile

Novozymes A/S produces and sells industrial enzymes, microorganisms, and probiotics in Denmark, rest of Europe, North America, Asia Pacific, the Middle East, Africa, Latin America, and internationally. The company offers protein solutions for the food and beverage industry. It also offers industrial hygiene, drain openers, hard surface, medical cleaning, septic tanks, ware washing, and professional laundry services.